Principal Financial Group Inc Cytom X Therapeutics, Inc. Transaction History

Principal Financial Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$1.53 - $2.89 $16,540 - $31,243	-10,811 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$2.67 - $4.68 $1,901 - $3,332	712 Added 7.05%	10,811 $29,000
Q4 2021 Feb 09, 2022	SELL	$3.87 - $7.39 $59,992 - $114,559	-15,502 Reduced 60.55%	10,099 $44,000
Q3 2021 Nov 09, 2021	BUY	$4.32 - $6.43 $45,986 - $68,447	10,645 Added 71.18%	25,601 $131,000
Q2 2021 Aug 10, 2021	SELL	$6.33 - $9.91 $53,444 - $83,670	-8,443 Reduced 36.08%	14,956 $94,000
Q1 2021 May 10, 2021	BUY	$6.6 - $9.0 $74,817 - $102,024	11,336 Added 93.97%	23,399 $181,000
Q4 2020 Feb 08, 2021	BUY	$6.47 - $7.9 $78,047 - $95,297	12,063 New	12,063 $79,000
Q4 2018 Feb 14, 2019	SELL	$12.69 - $18.61 $234,511 - $343,912	-18,480 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$18.04 - $26.41 $8,478 - $12,412	470 Added 2.61%	18,480 $342,000
Q2 2018 Aug 13, 2018	BUY	$21.38 - $29.68 $385,053 - $534,536	18,010 New	18,010 $0

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $58M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.